Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,018 public trials 2,029 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma

NCT04754100

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Norton Cancer Institute - St. Matthews - Medical Oncology/Hematology Candida Louisville, Kentucky, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • University of Cincinnati Cancer Center Cincinnati, Ohio, United States
View Trial Details
Completed

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

NCT01734928

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Southern Cancer Center Mobile, Alabama, United States
  • Arizona Oncology Tucson, Arizona, United States
  • University of Arizona Cancer Center Tucson, Arizona, United States
  • Alta Bates Comprehensive Cancer Center Berkeley, California, United States
View all 321 locations
View Trial Details
Completed

A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

NCT01682616

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +15 more
Locations
  • Moores Cancer Center at UC San Diego /ID# 70398 La Jolla, California, United States
  • Northwestern University Feinberg School of Medicine /ID# 71593 Chicago, Illinois, United States
  • North Shore University Hospital /ID# 71813 New Hyde Park, New York, United States
  • Duke Cancer Center /ID# 71393 Durham, North Carolina, United States
View Trial Details
Completed

Corneal Toxicity in Patients Treated by Belantamab Mafodotin

NCT05887206

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • CHU Dijon Dijon, France
  • CHU de Limoges - Hôpital Dupuytren Limoges, France
  • HCL- Croix Rousse Lyon, France
  • Clinique Monticelli-Vélodrome Marseille, France
View Trial Details
Completed

Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas

NCT03311412

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +11 more
Locations
  • South Texas Accelerated Research Therapeutics (START) Midwest Grand Rapids, Michigan, United States
  • The University of Texas MD Anderson Cancer Center Houston, Texas, United States
  • NEXT Oncology San Antonio, Texas, United States
  • Princess Margaret Cancer Centre Toronto, Ontario, Canada
View Trial Details

Related conditions